Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers

Hanguang Hu, Hang Zhang, Weiting Ge, Xiyong Liu, Sofia Loera, Peiguo Chu, Huarong Chen, Jiaping Peng, Lun Zhou, Shujing Yu, Ying Yuan, Suzhan Zhang, Lily Lai, Yun Yen, Shu Zheng

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is an extracellular matrix glycoprotein with malignancy-suppressing potential. The hypothesis that SPARCL1 reduces cancer invasiveness and predicts better survival in colorectal cancers (CRC) was investigated. Experimental Design: Stable SPARCL1 transfectants, RKO-SPARCL1, and corresponding vector control were constructed and implanted into nude mice to generate a mouse xenograft model of liver metastasis. Also, a retrospective outcome study was conducted on the COH set (222 CRCs) and ZJU set (412 CRCs). The protein expression level of SPARCL1 was determined by immunohistochemistry. The Kaplan-Meier and Cox analyses were used for survival analysis. The association of SPARCL1 with mesenchymal- epithelial transition (MET) was examined by reverse transcription PCR (RT-PCR) and Western blot analysis. Results: The ectopic expression of SPARCL1 significantly reduced the potential for anchorage-independent growth, migration, invasion and induced cell differentiation in RKO and SW620 cells. In mouse xenograft model, the expression of SPARCL1 significantly reduced the liver metastasis (P < 0.01). The patient-based studies revealed that the expression of SPARCL1 was related to better differentiation (P < 0.01), less lymph node involvement [OR, 0.67; 95% confidence interval (CI), 0.45-1.00], and less distant metastasis (OR, 0.38; 95% CI, 0.18-0.79). The Kaplan-Meier and Cox analysis showed that the expression of SPARCL1 was associated with better overall survival (log-rank: P < 0.01; HR, 0.57; 95% CI, 0.39-0.84). Transfection of SPARCL1 induced MET of colon cancer cells. Conclusion: SPARCL1 functions as a tumor suppressor promoting differentiation possibly via MET, which inhibits the aggressiveness of CRCs.

Original languageEnglish
Pages (from-to)5438-5448
Number of pages11
JournalClinical Cancer Research
Volume18
Issue number19
DOIs
Publication statusPublished - Oct 1 2012
Externally publishedYes

Fingerprint

Cysteine
Colorectal Neoplasms
Survival
Proteins
Epithelial-Mesenchymal Transition
Kaplan-Meier Estimate
Confidence Intervals
Neoplasm Metastasis
Heterografts
Neoplasms
Liver
Survival Analysis
Nude Mice
Colonic Neoplasms
Reverse Transcription
Extracellular Matrix
Transfection
Cell Differentiation
Glycoproteins
Research Design

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. / Hu, Hanguang; Zhang, Hang; Ge, Weiting; Liu, Xiyong; Loera, Sofia; Chu, Peiguo; Chen, Huarong; Peng, Jiaping; Zhou, Lun; Yu, Shujing; Yuan, Ying; Zhang, Suzhan; Lai, Lily; Yen, Yun; Zheng, Shu.

In: Clinical Cancer Research, Vol. 18, No. 19, 01.10.2012, p. 5438-5448.

Research output: Contribution to journalArticle

Hu, H, Zhang, H, Ge, W, Liu, X, Loera, S, Chu, P, Chen, H, Peng, J, Zhou, L, Yu, S, Yuan, Y, Zhang, S, Lai, L, Yen, Y & Zheng, S 2012, 'Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers', Clinical Cancer Research, vol. 18, no. 19, pp. 5438-5448. https://doi.org/10.1158/1078-0432.CCR-12-0124
Hu, Hanguang ; Zhang, Hang ; Ge, Weiting ; Liu, Xiyong ; Loera, Sofia ; Chu, Peiguo ; Chen, Huarong ; Peng, Jiaping ; Zhou, Lun ; Yu, Shujing ; Yuan, Ying ; Zhang, Suzhan ; Lai, Lily ; Yen, Yun ; Zheng, Shu. / Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 19. pp. 5438-5448.
@article{8a87c9ec006445c7a101d73802b5e4ef,
title = "Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers",
abstract = "Purpose: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is an extracellular matrix glycoprotein with malignancy-suppressing potential. The hypothesis that SPARCL1 reduces cancer invasiveness and predicts better survival in colorectal cancers (CRC) was investigated. Experimental Design: Stable SPARCL1 transfectants, RKO-SPARCL1, and corresponding vector control were constructed and implanted into nude mice to generate a mouse xenograft model of liver metastasis. Also, a retrospective outcome study was conducted on the COH set (222 CRCs) and ZJU set (412 CRCs). The protein expression level of SPARCL1 was determined by immunohistochemistry. The Kaplan-Meier and Cox analyses were used for survival analysis. The association of SPARCL1 with mesenchymal- epithelial transition (MET) was examined by reverse transcription PCR (RT-PCR) and Western blot analysis. Results: The ectopic expression of SPARCL1 significantly reduced the potential for anchorage-independent growth, migration, invasion and induced cell differentiation in RKO and SW620 cells. In mouse xenograft model, the expression of SPARCL1 significantly reduced the liver metastasis (P < 0.01). The patient-based studies revealed that the expression of SPARCL1 was related to better differentiation (P < 0.01), less lymph node involvement [OR, 0.67; 95{\%} confidence interval (CI), 0.45-1.00], and less distant metastasis (OR, 0.38; 95{\%} CI, 0.18-0.79). The Kaplan-Meier and Cox analysis showed that the expression of SPARCL1 was associated with better overall survival (log-rank: P < 0.01; HR, 0.57; 95{\%} CI, 0.39-0.84). Transfection of SPARCL1 induced MET of colon cancer cells. Conclusion: SPARCL1 functions as a tumor suppressor promoting differentiation possibly via MET, which inhibits the aggressiveness of CRCs.",
author = "Hanguang Hu and Hang Zhang and Weiting Ge and Xiyong Liu and Sofia Loera and Peiguo Chu and Huarong Chen and Jiaping Peng and Lun Zhou and Shujing Yu and Ying Yuan and Suzhan Zhang and Lily Lai and Yun Yen and Shu Zheng",
year = "2012",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-12-0124",
language = "English",
volume = "18",
pages = "5438--5448",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers

AU - Hu, Hanguang

AU - Zhang, Hang

AU - Ge, Weiting

AU - Liu, Xiyong

AU - Loera, Sofia

AU - Chu, Peiguo

AU - Chen, Huarong

AU - Peng, Jiaping

AU - Zhou, Lun

AU - Yu, Shujing

AU - Yuan, Ying

AU - Zhang, Suzhan

AU - Lai, Lily

AU - Yen, Yun

AU - Zheng, Shu

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is an extracellular matrix glycoprotein with malignancy-suppressing potential. The hypothesis that SPARCL1 reduces cancer invasiveness and predicts better survival in colorectal cancers (CRC) was investigated. Experimental Design: Stable SPARCL1 transfectants, RKO-SPARCL1, and corresponding vector control were constructed and implanted into nude mice to generate a mouse xenograft model of liver metastasis. Also, a retrospective outcome study was conducted on the COH set (222 CRCs) and ZJU set (412 CRCs). The protein expression level of SPARCL1 was determined by immunohistochemistry. The Kaplan-Meier and Cox analyses were used for survival analysis. The association of SPARCL1 with mesenchymal- epithelial transition (MET) was examined by reverse transcription PCR (RT-PCR) and Western blot analysis. Results: The ectopic expression of SPARCL1 significantly reduced the potential for anchorage-independent growth, migration, invasion and induced cell differentiation in RKO and SW620 cells. In mouse xenograft model, the expression of SPARCL1 significantly reduced the liver metastasis (P < 0.01). The patient-based studies revealed that the expression of SPARCL1 was related to better differentiation (P < 0.01), less lymph node involvement [OR, 0.67; 95% confidence interval (CI), 0.45-1.00], and less distant metastasis (OR, 0.38; 95% CI, 0.18-0.79). The Kaplan-Meier and Cox analysis showed that the expression of SPARCL1 was associated with better overall survival (log-rank: P < 0.01; HR, 0.57; 95% CI, 0.39-0.84). Transfection of SPARCL1 induced MET of colon cancer cells. Conclusion: SPARCL1 functions as a tumor suppressor promoting differentiation possibly via MET, which inhibits the aggressiveness of CRCs.

AB - Purpose: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is an extracellular matrix glycoprotein with malignancy-suppressing potential. The hypothesis that SPARCL1 reduces cancer invasiveness and predicts better survival in colorectal cancers (CRC) was investigated. Experimental Design: Stable SPARCL1 transfectants, RKO-SPARCL1, and corresponding vector control were constructed and implanted into nude mice to generate a mouse xenograft model of liver metastasis. Also, a retrospective outcome study was conducted on the COH set (222 CRCs) and ZJU set (412 CRCs). The protein expression level of SPARCL1 was determined by immunohistochemistry. The Kaplan-Meier and Cox analyses were used for survival analysis. The association of SPARCL1 with mesenchymal- epithelial transition (MET) was examined by reverse transcription PCR (RT-PCR) and Western blot analysis. Results: The ectopic expression of SPARCL1 significantly reduced the potential for anchorage-independent growth, migration, invasion and induced cell differentiation in RKO and SW620 cells. In mouse xenograft model, the expression of SPARCL1 significantly reduced the liver metastasis (P < 0.01). The patient-based studies revealed that the expression of SPARCL1 was related to better differentiation (P < 0.01), less lymph node involvement [OR, 0.67; 95% confidence interval (CI), 0.45-1.00], and less distant metastasis (OR, 0.38; 95% CI, 0.18-0.79). The Kaplan-Meier and Cox analysis showed that the expression of SPARCL1 was associated with better overall survival (log-rank: P < 0.01; HR, 0.57; 95% CI, 0.39-0.84). Transfection of SPARCL1 induced MET of colon cancer cells. Conclusion: SPARCL1 functions as a tumor suppressor promoting differentiation possibly via MET, which inhibits the aggressiveness of CRCs.

UR - http://www.scopus.com/inward/record.url?scp=84866918740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866918740&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-0124

DO - 10.1158/1078-0432.CCR-12-0124

M3 - Article

VL - 18

SP - 5438

EP - 5448

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -